Skip to Content
Merck
  • [A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis].

[A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis].

Minerva medica (1988-07-01)
M G Gambaro, P Genoni, D Berra
ABSTRACT

After considering the bacterial flora which is most common in relapses in patients with bronchitis, 40 patients with chronic bronchitis have been treated with tetroxoprim a recently synthetized benzyl pyrimidine associated with sulfadiazine. One 350 mg tablet was administered every 12 hours for different periods, from 7 to 14 days. This study has shown how tetroxoprim has a wide antibacterial range, how it is well tolerated and extremely powerful in treating relapses of chronic infections in bronchi.

MATERIALS
Product Number
Brand
Product Description

USP
Sulfadiazine, United States Pharmacopeia (USP) Reference Standard
Supelco
Sulfadiazine, VETRANAL®, analytical standard
Sigma-Aldrich
Sulfadiazine, 99.0-101.0%
Supelco
Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material
Sulfadiazine for identification of impurity F, European Pharmacopoeia (EP) Reference Standard
Sulfadiazine, European Pharmacopoeia (EP) Reference Standard